Chcesz wydać pracę habilitacyjną, doktorską czy monografię? Zrób to w Wydawnictwie Borgis – jednym z najbardziej uznanych w Polsce wydawców książek i czasopism medycznych. W ramach współpracy otrzymasz pełne wsparcie w przygotowaniu książki – przede wszystkim korektę, skład, projekt graficzny okładki oraz profesjonalny druk. Wydawnictwo zapewnia szybkie terminy publikacji oraz doskonałą atmosferę współpracy z wysoko wykwalifikowanymi redaktorami, korektorami i specjalistami od składu. Oferuje także tłumaczenia artykułów naukowych, skanowanie materiałów potrzebnych do wydania książki oraz kompletowanie dorobku naukowego.

© Borgis - Nowa Medycyna 2/2017, s. 86-97
*Małgorzata Kołodziejczak1, Iwona Sudoł-Szopińska1-3, Włodzimierz Zych1, 4
Current treatment options for Crohn’s fistula in ano – interdisciplinary problem
Współczesne leczenie przetok odbytu w chorobie Leśniowskiego-Crohna – problem interdyscyplinarny
1Warsaw Proctology Centre, Saint Elizabeth’s Hospital, Mokotów Medical Centre
Head of Centre: Associate Professor Małgorzata Kołodziejczak, PhD
2Department of Radiology, Eleonora Reicher National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw
Head of Department: Professor Iwona Sudoł-Szopińska, MD, PhD
3Department of Diagnostic Imaging, Second Faculty of Medicine, Medical University of Warsaw
Head of Department: Professor Wiesław Jakubowski, MD, PhD
4Polish Foundation of Gastroenterology, Warsaw
Head of Foundation: Bronisław Kotowski, MD
Streszczenie
Choroba Leśniowskiego-Crohna często, bo u 21-54% pacjentów, obejmuje dystalny odcinek przewodu pokarmowego. U prawie wszystkich chorych z zajęciem odbytnicy dochodzi do powstania przetoki odbytu. Objawy kliniczne przetoki są z reguły bardziej burzliwe niż przetoki o etiologii odkryptowej. Często jeszcze przed leczeniem operacyjnym występuje nietrzymanie stolca i gazów. Metodą z wyboru w diagnostyce przetok Leśniowskiego-Crohna jest rezonans magnetyczny, który ma przewagę nad endosonografią w obrazowaniu przetok wysokich, zwłaszcza ponadzwieraczowych oraz przetok rozgałęzionych i nawrotowych. Leczenie tych przetok ma charakter skojarzony i obejmuje farmakoterapię choroby podstawowej oraz leczenie chirurgiczne. W publikacji przedstawiono aktualne metody leczenia zachowawczego, wybrane rekomendacje European Crohn’s and Colitis Organisation (ECCO) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease z 2016 roku dotyczące postępowania zachowawczego i zabiegowego w leczeniu przetok odbytu oraz rekomendacje Polskiego Klubu Koloproktologii w tym zakresie. Lektura tych dokumentów dowodzi, że sukces terapii wynika z interdyscyplinarnego podejścia (gastroenterolog, chirurg i radiolog) do pacjenta z przetoką Leśniowskiego-Crohna.
Summary
Crohn’s disease frequently (in 21-54% of cases) involves the distal segment of the gastrointestinal tract. An anal fistula develops in nearly all patients with involved rectum. Its clinical signs tend to be more dramatic than those of fistulae with the cryptoglandular aetiology. Stool and gas incontinence is often seen before surgery. Magnetic resonance imaging is the method of choice in the diagnosis of fistulae associated with Crohn’s disease. This modality is superior to endosonography since it is able to visualise high fistulae, particularly supra-sphincteric, branching and recurrent. Their treatment is combined and encompasses pharmacotherapy for the underlying disease and surgery. This paper presents current methods of conservative treatment, selected recommendations of the European Crohn’s and Colitis Organisation (ECCO) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease from 2016 on conservative and surgical treatment of anal fistulae as well as recommendations of the Polish Coloproctology Club. These documents demonstrate that the success of therapy results from the interdisciplinary approach (gastroenterologist, surgeon and radiologist) to a patient with Crohn’s disease.
Introduction
Crohn’s disease frequently (in 21-54% of cases) involves the distal segment of the gastrointestinal tract. Nearly all patients develop an anal fistula, often a complex one, i.e. with branching and communication with the neighbouring organs (e.g. rectovaginal, rectovesical fistulae). Inflammatory lesions in this location also include non-healing fissures, inflammatory infiltrations and abscesses; patients often develop anorectal stenosis and anodermal flap hypertrophy.
In nearly half of the cases Crohn’s disease is present exclusively in the anorectal area. The presence of inflammatory lesions in the rectum is considered to be a negative prognostic factor for the course of the disease (1). In addition, a relationship between the serological and genetic type of a Crohn’s disease patient and the presence of inflammatory lesions in the rectum has been proven (2).
Population studies have demonstrated that the prevalence of fistulae increases with the duration of the disease and that fistulae are found in 21 to 23% of patients, including approximately 12% in the first year of the disease to 15% after five years, 21% after ten years, to as many as 26% of individuals after twenty years of the disease. There also exists a relationship between the occurrence of a fistula and the location of the underlying disease (3). In the case of inflammatory lesions that involve the ileum 12% of patients develop an anorectal fistula; with ileocaecal involvement 15% of patients develop an anal fistula; if the colon is involved, but the rectum is unaffected, approximately 41% of patients develop a fistula, whereas if the rectum is involved as well, a fistula occurs in 92% of patients. Perianal lesions may either precede clinically overt Crohn’s disease or be the first symptom of the disease, or co-occur with the intestinal manifestation (3).
Clinical presentation
The clinical symptoms of anal fistula associated with Crohn’s disease are usually more dramatic than those of cryptoglandular fistula. The characteristic symptoms of Crohn’s disease include pain around the anus resulting from partial stenosis of fistula canals and pus retention. Patients report leaking pus from the anus or from fistulae, oedema of the surrounding tissues, recurrent inflammation of the anus or abscesses. In the absence of appropriate surgical drainage septic complications may occur. Stool and gas incontinence is often seen already before surgery. It is caused by inflammatory lesions of the rectum and damage to sensory receptors of the transition zone responsible for the differentiation of rectal contents and by diarrhoeal stools and unproductive straining typical for the disease. In a large number of cases fistulae associated with Crohn’s disease are complex: high, branching (including horseshoe fistulae), often with concomitant abscesses or pus spillages in the ischiorectal and pelvic rectal fossae. They may form numerous internal outlets (multiple fistulae) or have numerous external openings (fig. 1-3).
Fig. 1. High branching fistula with multiple external outlets
Fig. 2. Branching fistula with a drain
Fig. 3. Seton drainage of a branching fistula – postoperative image
For endoscopically and histopathologically confirmed Crohn’s disease the diagnosis of a fistula is usually not difficult. However, for a person who reports to a physician with an anal fistula for the first time, the following should be taken into account in differential diagnosis (4):
– branching cryptoglandular fistulae,
– perineal apocrine glands inflammation,
– fistula in patients with compromised immunity (e.g. associated with HIV infection),
– complicated pilonidal cyst,
– furunculosis.
Aetiology and pathogenesis
The aetiology of anal fistulae associated with Crohn’s disease has not been fully discovered. According to one theory they develop as a result of penetration of abscesses from the side of the rectum or anal canal. It has not been fully confirmed if in every case of abscess the original aetiological factor is anal crypt infection. The current discussions focus on intestinal barrier damage and the role of genetic factors, changed intestinal microbiota and the activity of the immune system of the intestine. The development of inflammation in the rectal wall results from excessive activation of the immune system with leukocyte migration, uninhibited by feedback. Fistulae develop following epithelial damage associated with inflammation whose repair is compromised as a result of inhibited migration of fibroblasts to the lamina propria at the site of the damage (5). The function of the fibroblasts is taken over by the intestinal epithelium which transforms into myofibroblasts as a result of epithelial-mesenchymal transition mediated by cytokines: TGF-beta, TNF-alpha and IL-13, and other mediators. The intestinal epithelium cells lining the fistula canal also acquire the features of mesenchymal cells (6, 7). Another proposed mechanism of fistula formation is remodelling of the extracellular matrix, which is indicated by the increased expression of MMP-3 and MMP-9 metalloproteinases observed within the perimeter of the fistula canal (7). Bacterial infection may play a role, similarly to cryptoglandular fistulae. A link between NOD2 gene polymorphism and the risk of fistula formation has also been demonstrated (8).
Classification of fistulae associated with Crohn’s disease
Crohn’s anal fistulae, as do cryptoglandular fistulae, are included in the classic Parks’ classification, which divides fistulae into 4 types depending on the anatomical route of the fistula canal in relation to the external anal sphincter muscle (9). However, considering the specific nature of the disease, the American Gastroenterological Association has developed a separate classification of Crohn’s fistulae (10). It distinguishes between simple and complex fistulae. Simple fistulae include the ones which run below the dentate line, i.e. low intersphincteric and low transsphincteric fistulae with a single internal opening, without abscesses. All the remaining fistulae – complex fistulae are the ones which run above the dentate line, i.e. high intersphincteric, high transsphincteric, suprasphincteric and extrasphincteric fistulae, with multiple external openings, with possible concomitant abscesses or rectal stenosis and fistulae which communicate with the neighbouring organs (e.g. vagina, urinary bladder). The above classification does not account for the number of internal openings, although one may presume that all fistulae with more than one internal opening should be treated as multiple and complex.
Diagnostic investigation
Classically, the diagnostic investigation consists of history taking, physical examination, including primarily rectal examination, and additional examinations, such as endoscopy (to evaluate the extent and intensity of inflammatory lesions) and imaging (to determine the route of the fistula).
An element of diagnostic investigation which is often essential for the right diagnosis is examination under anaesthesia (EUA), which should be conducted in an operating room. This allows for performing drainage of the fistula canal if necessary and thus for limiting inflammation and preventing abscesses.
Diagnostic imaging
The basic imaging examination for the diagnosis of anal fistulae is transrectal ultrasound (endosonography). It is highly effective for the pre- and postoperative diagnosis of the majority of anal fistulae, especially simple and primary (non-recurrent) as well as low fistulae. Endosonography visualises anal sphincters very well (11-16). The disadvantage of this method is limited imaging field and insufficient differentiation between tissues, especially between a recurrent fistula and a scar.
Pelvic magnetic resonance imaging (MRI) is characterised by a wide field of view (a scan conducted using a surface coil covers the whole pelvis), multiplane imaging and the ability to identify tissues affected by inflammation (fistula, branching, inflammatory infiltration, abscess), especially in contrast-enhanced sequences (17, 18). MRI has a definite advantage over endosonography in the imaging of high fistulae, especially suprasphincteric ones, and in differentiating fistulae, branching and leaks from scars/postoperative lesions (19) (fig. 4a-d). This is important because of the nature of anal fistulae in patients with Crohn’s disease: approximately half of these fistulae are high, including suprasphincteric and often branching fistulae.
Fig. 4a-d. MRI of anal fistula: transsphincteric fistula on the posterior right side (a), covering 1/2 of the external sphincter length (arrows); internal outlet at midline from the posterior (arrow), loss of 70% of the posterior perimeter of the internal sphincter (b); at the level of the anorectum a branch surrounding the right perimeter of the rectum (arrows) (c); in the sagittal section the range of the fistula in the long axis is seen (length) (d)
3D endosonography scans performed by the present authors have demonstrated that endosonography remains the primary technique for imaging anal fistulae and sphincters (12). It allows for the determination of the type and height of fistulae, the location of branching and internal outlet with a high level of precision. It visualises the integrity and echostructure of the sphincters very well, which is particularly important in individuals with Crohn’s disease.
Treatment
The treatment of Crohn’s fistulae is combined and includes pharmacotherapy for the underlying disease as well as surgery. For a clinician effective treatment means fistula canal healing and no recurrence of abscesses and inflammation of the anorectal area. There is no definitely established follow-up period to evaluate the efficacy of therapy; however, the authors’ own practical observations indicate that the highest rate of fistula recurrence is found up to one year after the completion of therapy (pharmacotherapy or surgery).
Conservative treatment
Despite the continuous development of surgery the efficacy of Crohn’s fistula treatment is still limited. The following factors are important for planning the treatment:
– determination of the anatomical location of fistula opening and route,
– confirmation or exclusion of local inflammation (abscess),
– staging of the underlying disease (gastroscopy, colonoscopy),
– determination of neighbouring organ involvement and its impact on the general symptoms and quality of life impairment,
– assessment of the patient’s nutritional status.
Although fistulae are usually located in the perianal area, the number of good-quality clinical studies concerning every form of treatment of the disease is not sufficient to form any definite recommendations. The currently applied methods of conservative treatment of Crohn’s fistulae are presented below with literature references.
Antibiotics
The only available data confirming the efficacy of antibiotics come from numerous reports of uncontrolled case series (20, 21). A randomised clinical study on a small group of patients comparing metronidazole 2 x 500 mg (n = 8) with ciprofloxacin 2 x 500 mg (n = 10), with placebo control (n = 7) did not demonstrate superiority of any of the antibiotics over placebo in terms of clinical improvement or shortening drainage time (22). With combined use of both medicines subjective improvement and reduction in complaints were noted; however, the fistula did not heal and recurrence was observed (22).
In one of the latest systematic reviews of the effect of antibiotics on the healing of fistula canal in a group of 123 patients with Crohn’s disease treated with metronidazole or ciprofloxacin monotherapy it was demonstrated that antibiotic therapy contributed to the reduction of fistula recurrence rate (23).
Immunomodulatory treatment (azathioprine, 6-mercaptopurine)
There is no randomised controlled trial evaluating the effect of azathioprine or 6-mercaptopurine on fistula healing in patients with Crohn’s disease. However, there are data which support the use of this group of medicines coming from studies in which fistula canal healing was a secondary endpoint and from uncontrolled case series reports. These reports show clinical efficacy for both azathioprine and 6-mercaptopurine (24, 25).
Biological treatment (anti-TNF-alpha)
1. Infliximab evaluated in randomised trials proved to be the first effective medicine for anal fistula healing and prevention of recurrence in one-year follow-up. Three infusions were used in a typical regimen at week 0, 2 and 6 at 5 mg/kg of body mass and complete healing of fistula canal was achieved in 55% of patients (26). In the ACCENT II study, at week 14 fistula canal healing was achieved in 69% of patients (27). Subsequently patients in whom fistula canal healing was achieved were randomised to two trial arms, one of which continued to receive infusions of the drug every 8 weeks and the other one received placebo. At week 54 the proportion of patients who experienced sustained healing of fistulae in the group treated with the active drug was nearly twice as high as in the placebo group (36 vs. 19%). Maintenance therapy reduced the number of hospitalisations and surgical procedures (28). This effect was later confirmed in non-placebo-controlled studies on patients at the Mayo Clinic and Boston centre (29, 30). In another study involving nearly 5-year retrospective follow-up sustained fistula remission was found in 2/3 of a group of 156 patients with anal fistulae associated with Crohn’s disease. Positive prognostic factors included combined treatment, limiting drainage time to no more than 34 weeks and long-term drug administration (31).
2. Adalimumab was initially evaluated in two short-term CLASSIC-I (32) and GAIN (33) studies in which fistula canal healing was adopted as a secondary endpoint and did not demonstrate any superiority over placebo. It was only in a larger study – CHARM that the superiority of the drug over placebo was found at week 26 (30 vs. 13%) and week 56 (33 vs. 13%). In another study the efficacy of the medicine for fistula healing varied depending on the selection of patients and study methodology and was approximately 40% (34).
3. Certolizumab evaluated in randomised, placebo-controlled studies (PRECiSE1 and PRECiSE2) did not demonstrate any significant superiority over placebo in the process of fistula healing, especially in maintaining disease remission (35).
Combined antibiotic and biological treatment
A pilot (36) and a randomised (37) study demonstrated that combined use of ciprofloxacin and a TNF-alpha inhibitor was more effective in fistula treatment than biologic monotherapy in 12-week follow-up.
Other medicines
Experience with intravenous cyclosporine in patients with Crohn’s fistulae comes from the observation of small groups of patients only (38). Some of the patients experienced improvement, which, however, was not sustained after changing the route of administration to oral. Data on oral tacrolimus indicate its limited effect on fistula healing, with no impact on sustaining remission (39).
Other conservative therapies
A small number of reports of single cases or non-placebo-controlled case series indicate a beneficial effect of enteral and parenteral nutrition, mycophenolate mofetil, methotrexate, thalidomide, granulocyte colony stimulating factor (GCSF) or hyperbaric therapy for fistula healing. However, these therapies cannot be recommended for routine clinical practice (40). There are single reports of a beneficial effect of locally administered auto- and allogenic stem cells (41, 42), which may set a new direction for the search of more effective therapies.
Maintenance therapy
There are no data on the efficacy of immunomodulatory treatment following the induction of remission achieved by using biologics as monotherapy or as adjuvant treatment during maintenance biological therapy. In the ACCENT II study approximately 75% of patients included in the trial used immunomodulatory drugs; however, only 30% of them continued the therapy during anti-TNF-alpha treatment. Maintenance infliximab therapy reduces the number of hospitalisations and surgical procedures (28). Chronic adalimumab treatment is effective for remission maintenance; however, the effect of this drug on the reduction of hospitalisation time and the need for surgical intervention is unknown.
Surgery
The procedure should optimally be conducted during disease remission when inflammatory lesions are low in intensity (except for fistula canal drainage, which is often essential for limiting infection). Due to compromised sphincter function, sphincter-sparing surgical methods are selected.
Fistulotomy is only used in low intersphincteric and low transsphincteric fistulae, i.e. covering less than 30% of the external anal sphincter mass, in patients with good sphincter function. In the remaining cases, in complex fistulae loose seton drainage of the fistula canal should nearly always be used at the first stage of treatment. Cutting seton is not used since the aim of the treatment is not to cut the sphincter, but to limit inflammation and prevent abscesses (43).
The first stage of fistula treatment in Crohn’s disease should involve limiting infection: opening abscesses, applying loose seton fistula drainage, using antibiotic therapy (usually ciprofloxacin with metronidazole, sometimes with additional thiopurine) and achieving remission of the underlying disease. It should also involve continuous surgical and gastroenterological care.
After setting fistula drainage the following may be done depending on the individual situation:
1. Keep permanent drainage.
2. For a high and branching fistula, following the resolution of inflammation, start biological treatment (efficacy at 75%) (44).
3. For a high and simple fistula, following the resolution of inflammation, perform a sphincter-sparing surgery, e.g. close the internal outlet with a rectal mucosal flap or conduct a LIFT operation. A surgery involving suturing a flap should not be performed if exacerbated inflammatory lesions are present in the rectum.
4. Another option may be to perform such a procedure during infliximab therapy; its efficacy is estimated to be 64% with slight incontinence in 9.4% of patients (45).
5. Following the resolution of inflammation perform a LIFT operation; complete fistula healing is estimated to be involved in 67% of cases, with no incontinence symptoms (46).
6. In non-branching fistulae with a straight route glue or plugs may be used.
If the above methods of treatment are ineffective, the formation of a colostomy with a spared rectum or rectal excision is the remaining option.
The guidelines of the Polish Coloproctology Club concerning the treatment of anal fistulae associated with Crohn’s disease developed by Professor Roman Herman (which are close to the ones proposed above) are presented below:
1. Active proctocolitis associated with Crohn’s disease is a contraindication to local surgical treatment to cure an anal (rectal) fistula.
2. Low anal fistulae (in the absence of rectal inflammation) may be treated with fistulotomy with appropriate conservative treatment of the underlying disease. The patient should be informed of the risk of slow wound healing.
3. Complex fistulae may be treated palliatively with long-term drainage using loose seton. Attempts at surgical treatment may be made only when effective conservative treatment of Crohn’s disease has been applied, usually after an attempt at closing the fistula with anti-TNF-alpha treatment. A procedure using a pedunculated flap (mucosal and muscular rectal flap or anodermal flap) may be effective.
ECCO recommendations of 2016 (3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease) also include the subject of conservative and surgical treatment of anal fistulae (47). They are similar to the guidelines of the Polish Coloproctology Club, but provide a more detailed account of the recommended drug therapies:
1. A symptomatic simple fistula requires treatment. Seton drainage combined with antibiotics (metronidazole and/or ciprofloxacin) is the treatment of choice. For a recurrent or antibiotic-resistant simple fistula the use of thiopurines or biologics may be considered.
2. Active Crohn’s disease of the large and/or small intestine should be subjected to intensive conservative treatment with concomitant surgical treatment of the fistula.
3. Infliximab or adalimumab combined with a drainage procedure should be used as first-line treatment of a complex anal fistula. Combined ciprofloxacin and anti-TNF-alpha treatment improves short-term results. In order to improve the efficacy of TNF-alpha inhibitors, treatment combined with thiopurines may be considered.
4. Thiopurines, infliximab or adalimumab, seton drainage or combined drainage and conservative treatment are recommended for sustaining remission of anorectal Crohn’s disease.
Conclusions
This paper discusses selected problems concerning the treatment of anal fistulae associated with Crohn’s disease. The still high rate of treatment failures indicates that the treatment of this type of fistulae is still an open issue. New pharmacotherapies and anal sphincter-sparing surgical treatment methods have been constantly searched for. The success of therapy is undoubtedly dependent on a multidisciplinary approach of a number of specialists – gastroenterologist, surgeon and radiologist.
Piśmiennictwo
1. Aguilera-Castro L, Ferre-Aracil C, Garcia-Garcia-de-Paredes A et al.: Management of complex perianal Crohn’s disease. Ann Gastroenterol 2017; 30(1): 33-44.
2. Kaur M, Panikkath D, Yan X et al.: Perianal Crohn’s Disease is Associated with Distal Colonic Disease, Stricturing Disease Behavior, IBD-Associated Serologies and Genetic Variation in the JAK-STAT Pathway. Inflamm Bowel Dis 2016; 22(4): 862-869.
3. Schwartz DA, Loftus EV Jr, Tremaine WJ et al.: The natural history of fistulizing Crohn‘s disease in Olmsted County, Minnesota. Gastroenterology 2002; 122(4): 875-880.
4. Kołodziejczak M: Rozpoznawanie i leczenie przetok w chorobie Leśniowskiego-Crohna. [W:] Kołodziejczak M, Sudoł-Szopińska I (red.): Diagnostyka i leczenie ropni i przetok odbytu. Wydawnictwo Borgis, Warszawa 2008: 207-215.
5. Dignass AU: Mechanisms and modulation of intestinal epithelial repair. Inflamm Bowel Dis 2001; 7: 68-77.
6. Frei SM, Hemsley C, Pesch T et al.: The role for dickkopf-homolog-1 in the pathogenesis of Crohn’s disease-associated fistulae. PLoS One 2013; 8: e78882.
7. Scharl M, Rogler G: Pathophysiology of fistula formation in Crohn’s disease. World J Gastrointest Pathophysiol 2014; 5: 205-212.
8. Radlmayr M, Török HP, Martin K, Folwaczny C: The c-insertion mutation of the NOD2 gene is associated with fistulizing and fibrostenotic phenotypes in Crohn’s disease. Gastroenterology 2002; 122: 2091-2092.
9. Parks AG, Gordon PH, Hardcastle JD: A classification of fistula in ano. Br J Surg 1976; 63: 1-12.
10. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB: AGA technical review on perianal Crohn’s disease. Gastroenterology 2003; 125: 1508-1530.
11. Burdan F, Sudoł-Szopińska I, Starosławska E et al.: Magnetic resonance imaging and endorectal ultrasound for diagnosis of rectal lesions. Eur J Med Res 2015; 20(1): 4.
12. Kołodziejczak M, Santoro GA, Obcowska A et al.: Three-dimensional endoanal ultrasound is accurate and reproducible in determining type and height of anal fistulae. Eur J Med Res 2015; 20: 4.
13. Criad JM, Salto LG, Rivas PF et al.: MR Imaging Evaluation of Perianal Fistulas: Spectrum of Imaging Features. Radio Graphics 2012; 32:175-194.
14. van Outryve M, Pelckmans P, Fierens H et al.: Transrectal ultrasonographic examination of the anal sphincter. Acta Gastroenterol Belg 1994; 57(1): 26-27.
15. Manes G, Maconi G, Saibeni S: New horizons in the imaging of perianal Crohn’s disease: transperineal ultrasonography. Expert Rev Gastroenterol Hepatol 2017; 28: 1-8.
16. van Outryve MJ, Pelckmans PA, Michielsen PP, van Maercke YM: Value of transrectal ultrasonography in Crohn’s disease. Gastroenterology 1991; 101(5): 1171-1177.
17. Beckingham IJ, Spencer JA, Ward J et al.: Prospective evaluation of dynamic contrast enhanced magnetic resonance imaging in the evaluation of fistula in ano. Br J Surg 1996; 83(10): 1396-1398.
18. Buchanan G, Halligan S, Williams A et al.: Effect of MRI on clinical outcome of recurrent fistula-in-ano. Lancet 2002; 360(9346): 1661-1662.
19. Alabiso ME, Iasiello F, Gianluca Pellino G et al.: 3D-EAUS and MRI in the Activity of Anal Fistulas in Crohn’s Disease. Gastroenterology Res Pract 2016; 2016: ID 1895694.
20. Bernstein LH, Frank MS, Brandt LJ, Boley SJ: Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 1980; 79(2): 357-365.
21. Brandt LJ, Bernstein LH, Boley SJ, Frank MS: Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982; 83(2): 383-387.
22. Thia KT, Mahadevan U, Feagan BG et al.: Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2009; 15(1): 17-24.
23. Khan KJ, Ullman TA, Ford AC et al.: Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterology 2011; 106(4): 661-673.
24. Pearson DC, May GR, Fick GH, Sutherland LR: Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123(2): 132-142.
25. Korelitz BI, Adler DJ, Mendelsohn RA, Sacknoff AL: Long-term experience with 6-mercaptopurine in the treatment of Crohn’s disease. Am J Gastroenterology 1993; 88(8): 1198-1205.
26. Present DH, Rutgeerts P, Targan S et al.: Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340(18): 1398-1405.
27. Sands BE, Anderson FH, Bernstein CN et al.: Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 876-885.
28. Lichtenstein GR, Yan S, Bala M et al.: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn‘s disease. Gastroenterology 2005; 128(4): 862-869.
29. Ricart E, Panaccione R, Loftus EV et al.: Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterology 2001; 96(3): 722-729.
30. Farrell RJ, Shah SA, Lodhavia PJ et al.: Clinical experience with infliximab therapy in 100 patients with Crohn’s disease. Am J Gastroenterology 2000; 95(12): 3490-3497.
31. Bouguen G, Siproudhis L, Gizard E et al.: Long-term outcome of perianal fistulizing Crohn’s disease treated with infliximab. Clin Gastroenterol Hepatol 2013; 11: 975-981.
32. Hanauer SB, Sandborn WJ, Rutgeerts P et al.: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn‘s disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2): 323-333.
33. Sandborn WJ, Rutgeerts P, Enns R et al.: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146(12): 829-838.
34. Lichtiger S, Binion DG, Wolf DC et al.: The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn‘s disease who failed prior infliximab therapy. Aliment Pharmacol Therapeutics 2010; 32(10): 1228-1239.
35. Sandborn WJ, Feagan BG, Stoinov S et al.: Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357(3): 228-238.
36. West RL, van der Woude CJ, Hansen BE et al.: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Therapeutics 2004; 20(11-12): 1329-1336.
37. Dewint P, Hansen BE, Verhey E et al.: Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn’s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014; 63(2): 292-299.
38. Egan LJ, Sandborn WJ, Tremaine WJ: Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn’s disease with intravenous cyclosporine. Am J Gastroenterology 1998; 93(3): 442-448.
39. Sandborn WJ, Present DH, Isaacs KL et al.: Tacrolimus for the treatment of fistulas in patients with Crohn‘s disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125(2): 380-388.
40. Sandborn WJ, Fazio VW, Feagan BG et al.: AGA technical review on perianal Crohn’s disease. Gastroenterology 2003; 125(5): 1508-1530.
41. de la Portilla F, Alba F, Garcia-Olmo D et al.: Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013; 28(3): 313-323.
42. Ciccocioppo R, Bernardo ME, Sgarella A et al.: Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 2011; 60(6): 788-798.
43. Marzo M, Felice C, Pugliese D et al.: Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J Gastroenterol 2015; 21(5): 1394-1403.
44. Haennig A, Staumont G, Lepage B et al.: The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn’s disease. Colorectal Dis 2015; 17(4): 311-319.
45. Soltani A, Kaiser AM: Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum 2010; 53: 486-495.
46. Gingold DS, Murrell ZA, Fleshner PR: A prospective evaluation of the ligation of the intersphincteric tract procedure for complex anal fistula in patients with Crohn’s disease. Ann Surg 2014; 260: 1057-1061.
47. Gionchett P 3rd, Dignass A, Danese S et al.: European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016. Part 2: Surgical Management and Special Situations. J Crohns Colitis 2017; 11(2): 135-149.
otrzymano: 2017-04-13
zaakceptowano do druku: 2017-05-04

Adres do korespondencji:
*Małgorzata Kołodziejczak
Warszawski Ośrodek Proktologii Szpital św. Elżbiety – Mokotowskie Centrum Medyczne
ul. Goszczyńskiego 1, 02-615 Warszawa
tel. +48 (22) 542-08-16
drkolodziejczak@o2.pl

Nowa Medycyna 2/2017
Strona internetowa czasopisma Nowa Medycyna